Mer­ck pays Mod­er­na $250M to con­tin­ue Keytru­da, can­cer vac­cine com­bo stud­ies

Af­ter near­ly six years of work­ing to­geth­er, Mer­ck and Mod­er­na are tak­ing the next step in their can­cer vac­cine part­ner­ship.

Mer­ck is opt­ing in­to a deal to “joint­ly de­vel­op and com­mer­cial­ize” one of Mod­er­na’s per­son­al­ized can­cer shots in com­bi­na­tion with the block­buster drug Keytru­da, the com­pa­nies an­nounced Wednes­day. As part of the op­tion, Mer­ck will pay Mod­er­na $250 mil­lion to ad­vance the com­bo, and the com­pa­nies will share costs and prof­its equal­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER